ATNM Actinium Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: ATNM

Price (delayed)

$5.26

Market cap

$144.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.93

Enterprise value

$63.43M

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application ...

Highlights
The debt has decreased by 15% YoY and by 5% from the previous quarter
ATNM's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
ATNM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.actiniumpharma.com
Peers: ADXS BMRN

Key stats

What are the main financial stats of ATNM
Market
Shares outstanding
27.41M
Market cap
$144.19M
Enterprise value
$63.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$50.14M
EBITDA
-$49.39M
Free cash flow
-$47.79M
Per share
EPS
-$1.93
Free cash flow per share
-$1.77
Book value per share
$1.61
Revenue per share
$0
TBVPS
$3.29
Balance sheet
Total assets
$88.94M
Total liabilities
$45.36M
Debt
$2.21M
Equity
$43.58M
Working capital
$76.92M
Liquidity
Debt to equity
0.05
Current ratio
9.87
Quick ratio
9.57
Net debt/EBITDA
1.64
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.6%
Return on equity
-91%
Return on invested capital
N/A
Return on capital employed
-62.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATNM stock price

How has the Actinium Pharmaceuticals stock price performed over time
Intraday
1.54%
1 week
25.84%
1 month
15.6%
1 year
-48.83%
YTD
-50.61%
QTD
-11.15%

Financial performance

How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$52.87M
Net income
-$50.14M
Gross margin
N/A
Net margin
N/A
ATNM's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
ATNM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The operating income has dropped by 71% year-on-year and by 9% since the previous quarter
ATNM's net income has dropped by 65% year-on-year and by 8% since the previous quarter

Growth

What is Actinium Pharmaceuticals's growth rate over time

Valuation

What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 48% YoY and by 6% from the previous quarter
The equity has declined by 39% year-on-year and by 18% since the previous quarter
The price to book (P/B) is 18% lower than the last 4 quarters average of 3.9 and 16% lower than the 5-year quarterly average of 3.8
ATNM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Actinium Pharmaceuticals business performance
ATNM's return on equity has dropped by 119% year-on-year and by 22% since the previous quarter
The company's return on assets has shrunk by 61% YoY and by 16% QoQ

Dividends

What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNM.

Financial health

How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 96% more than its total liabilities
The quick ratio has decreased by 29% YoY and by 4% from the previous quarter
Actinium Pharmaceuticals's current ratio has decreased by 27% YoY and by 5% QoQ
The debt is 95% less than the equity
The equity has declined by 39% year-on-year and by 18% since the previous quarter
The company's debt to equity rose by 25% QoQ and by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.